KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Matthew D Galsky, Alexandra Drakaki, Arnab Basu, Bradley McGregor, Jens Bedke, Yohann Loriot, Eiji Kikuchi, Jun Guo, Benjamin Garmezy, Srikala S Sridhar, Parminder Singh, Vadim S Koshkin, Mark Fleming, Gunnar Klauss, Daisy Lin, Chelsea Liu, Andrea B Apolo, Thomas Powles

Future Oncol 22(12) 1387-1396

PMID42142358
PMCIDPMC13203067
DOI10.1080/14796694.2026.2663956
发表日期2026-05-16
摘要

摘要

Enfortumab vedotin (EV) plus pembrolizumab is the first-line standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). However, randomized data to guide treatment after progression on EV plus pembrolizumab are limited. Datopotamab deruxtecan (Dato-DXd), a trophoblast cell surface antigen 2-directed antibody-drug conjugate, has demonstrated durable efficacy and a manageable safety profile in patients with la/mUC. TROPION-Urothelial03 is a global, multicenter, randomized, open-label, phase II/III trial comparing the efficacy and safety of Dato-DXd plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy in patients with la/mUC and disease progression on or after EV plus pembrolizumab. In Part A (phase II), ~60 patients will be randomized 1:1 to Dato-DXd 4 or 6 mg/kg plus platinum chemotherapy to determine optimal dosing. In Part B (phase III), ~570 patients will be randomized 1:1 to receive Dato-DXd at the recommended phase III dose plus platinum chemotherapy or gemcitabine plus platinum chemotherapy. The primary endpoint of Part A is objective response rate (ORR); the dual primary endpoints of Part B are progression-free survival (PFS) by blinded independent central review (BICR) and overall survival. Secondary endpoints include duration of response by investigator (Part A), and PFS by investigator and ORR by BICR and investigator (Part B).Clinical trial registration: www.clinicaltrials.gov identifier is NCT07129993.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。